Results 61 to 70 of about 25,234 (166)

SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series

Case Reports in Nephrology
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in patients with kidney disease and have been shown to increase serum magnesium levels.
Fatima Ayub, Praveen Errabelli, Abedalrahman Almashayekh, Ahmed Abdallah, Md Rajibul Hasan, Manisha Singh, Nithin Karakala, Joseph Hunter Holthoff   +7 more
doaj   +1 more source

SGLT2 inhibitor

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
Akira Nishiyama, Hirofumi Hitomi, Daisuke Nakano   +2 more
openaire   +2 more sources

A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database

Scientific Reports
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of drugs used in the clinical management of patients with type 2 diabetes, and their prescriptions have been increasing in recent years.
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji, Kohei Shiota, Nanaka Ichihara, Moe Yamashita, Yuka Nokura, Tomofumi Yamazaki, Kana Sugishita, Hideyuki Tanaka, Hirofumi Tamaki, Motoyuki Ishiguro, Kazuhiro Iguchi, Mitsuhiro Nakamura   +16 more
doaj   +1 more source

Ertugliflozin - SGLT2 inhibitor [PDF]

Interní medicína pro praxi, 2019
openaire   +1 more source

SGLT2 Inhibitor [PDF]

, 2020
openaire   +1 more source

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

Vascular Health and Risk Management, 2016
James W Reed Morehouse School of Medicine, Atlanta, GA, USA Abstract: SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM).
Reed JW
doaj  

Repurposing SGLT2 inhibitors [PDF]

Nature Reviews Drug Discovery, 2018
openaire   +1 more source

Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use. [PDF]

J Korean Med Sci
Bae S, Yun D, Kim J, Park S, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, Han SS.   +9 more
europepmc   +1 more source

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy. [PDF]

Am Heart J Plus
Sheashaa H, Ibrahim R, Pham HN, Awad K, Scalia IG, Farina JM, Tamarappoo B, Holloway C, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management. [PDF]

Front Endocrinol (Lausanne)
Deng B, Liu W, Chu Q.
europepmc   +1 more source